Ovarian cancer trials recruiting in Tennessee
All Ovarian cancer trials nationally
19
Recruiting in Tennessee
4
Cities with sites
Cities in Tennessee
Nashville 19Memphis 3Chattanooga 1Knoxville 1
Recruiting trials in Tennessee
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- DESTINY-PANTUMOUR04
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease